Asunto(s)
Anemia , Transfusión de Sangre Intrauterina , Femenino , Humanos , Embarazo , Estudios RetrospectivosAsunto(s)
Incompatibilidad de Grupos Sanguíneos/terapia , Transfusión de Sangre Intrauterina/métodos , Transfusión de Eritrocitos/métodos , Transfusión Feto-Fetal/terapia , Embarazo Gemelar/sangre , Incompatibilidad de Grupos Sanguíneos/embriología , Incompatibilidad de Grupos Sanguíneos/inmunología , Eritrocitos/inmunología , Femenino , Transfusión Feto-Fetal/sangre , Transfusión Feto-Fetal/inmunología , Humanos , Embarazo , Embarazo Gemelar/inmunología , Gemelos MonocigóticosRESUMEN
BACKGROUND: Blood transfusion is common in neonatology, especially in preterm or low birth weight infants. Recommendations were proposed by the French National Authority of Health (HAS) in 2014 and 2015 for red blood cells and platelet transfusion respectively, but an heterogeneity of practical attitudes persist. The objective of this survey is to evaluate transfusion practices in neonatal intensive care units. METHODS: Investigation of practice of neonatal transfusion was organized among 68 neonatal intensive care unit (level 3) between September 2016 and May 2017, by mailing survey focused on systematic training of nurses, patient identification, immunohematology, information and technical aspects of blood components administration. RESULTS: Twenty-three neonatal intensive care units among the 68s answered the questionnaire. One thousand five hundred sixty seven neonates were transfused and 3382 blood products were administered. The results highlight a consensual attitude concerning the procedures of patient identification, immunohematology tests and blood products administration. However, heterogeneity remains concerning information of the parents or the person with parental authority, immediate and delayed follow-up and devices used for the transfusion. However HAS guidelines (2014 and 2015) appear to be well applied by clinicians for blood products, specifications and calcul of transfused volume based on gestational age and weight.
Asunto(s)
Seguridad de la Sangre/estadística & datos numéricos , Transfusión Sanguínea/estadística & datos numéricos , Adhesión a Directriz/estadística & datos numéricos , Pautas de la Práctica en Medicina/estadística & datos numéricos , Francia , Encuestas Epidemiológicas , Humanos , Recién Nacido , Unidades de Cuidado Intensivo Neonatal/estadística & datos numéricos , NeonatologíaRESUMEN
Glucose-6-phosphate dehydrogenase (G6PD) deficiency is the most common human enzyme defect often presenting with neonatal jaundice and/or hemolytic anemia. G6PD hemolytic events are linked with exposure to a pro-oxidant agent. We here report three cases of initial G6PD crises in breastfed children secondary to maternal consumption of a tonic drink which contains quinine. Quinine was found in breast milk of one of the mothers after she consumed tonic water. CONCLUSION: The amount of quinine that is transmitted through breast milk appears to be sufficient to induce G6PD crises in breastfed children. We hence recommend that consumption of quinine-containing sodas during breastfeeding should be avoided in populations with a high prevalence of G6PD deficiency. What is Known: ⢠G6PD hemolytic events are linked with exposure to a pro-oxidant agent. ⢠Ingestion of fava beans by a mother who was breastfeeding has been reported to induce a neonatal G6PD crisis. What is New: ⢠Maternal consumption of tonic drink which contains quinine appears to be sufficient to induce G6PD crises in breastfed children. ⢠Maternal consumption of quinine-containing sodas during breastfeeding should be avoided in populations with a high prevalence of G6PD deficiency.
Asunto(s)
Lactancia Materna , Bebidas Gaseosas/toxicidad , Deficiencia de Glucosafosfato Deshidrogenasa/inducido químicamente , Oxidantes/toxicidad , Quinina/toxicidad , Femenino , Deficiencia de Glucosafosfato Deshidrogenasa/diagnóstico , Humanos , Lactante , Recién Nacido , MasculinoRESUMEN
Glucose-6-phosphate dehydrogenase (G6PD) deficiency is the most common human erythrocyte enzyme defect, estimated to affect approximately 4 million people worldwide. It is associated with severe neonatal hyperbilirubinemia, which may lead to bilirubin encephalopathy and kernicterus, and with hemolytic crisis. G6PD deficiency is an X-linked enzymopathy affecting hemizygous males, homozygous females, and also a subset of heterozygous females via chromosome X inactivation. We report four cases of female newborns with neonatal hyperbilirubinemia related to a G6PD deficiency and followed by the Centre national de référence en hémobiologie périnatale (CNRHP) from November 2013 to July 2014. Clinical and biological characteristics suggested G6PD deficiency (jaundice observed within the first 24h, severe hyperbilirubinemia, associated with regenerative hemolytic anemia, low response to phototherapy, ethnic origin of the parents from high-incident geographical regions). The family investigations revealed a deficit in G6PD in one of the parents who was unaware of this deficit until then. This article aims to make neonatologists and pediatricians aware of the need to search for an etiology for any severe hyperbilirubinemia and to raise G6PD deficiency in male and female newborns in case of hyperbilirubinemia with hemolysis.
Asunto(s)
Deficiencia de Glucosafosfato Deshidrogenasa/diagnóstico , Femenino , Deficiencia de Glucosafosfato Deshidrogenasa/complicaciones , Humanos , Hiperbilirrubinemia Neonatal/etiología , Recién Nacido , Estudios RetrospectivosRESUMEN
OBJECTIVES: The aim of our study was to evaluate in utero blood transfusion's (IUT) performed in France, among the French prenatal diagnosis centers in order to study the etiology of severe anemia requiring IUT. METHODS: We conducted a national retrospective descriptive study between 2011 and 2014. The data were collected using a survey sent by email to all French prenatal diagnosis centers. RESULTS: Among the 49 centers, 18 (38 %) had performed at least one IUT during the study period. The geographical repartition of these centers was appropriate for the "Aquitaine Pyrénées" region. Five centers performed 68 % of the national activity and one center performed 40 % the national activity. Each year, a mean of 204 IUTs were performed in 113 pregnancies. The principal etiology of severe fetal anemia requiring IUT was hemolytic disease of the fetus (69 % of the etiologies) with anti-RhD being the most prevalent antibody. The second etiology was represented by parvovirus B19 infection (17 % of IUTs). CONCLUSION: The French IUT activity was stable in numbers and indications during the study period. A national register could be set up in order to better evaluate prospectively the number of pregnancies concerned by IUT and to study the prevalence of hemolytic disease of the fetus due to anti-RhD antibodies.
Asunto(s)
Transfusión de Sangre Intrauterina/métodos , Eritroblastosis Fetal/terapia , Transfusión de Eritrocitos/métodos , Anemia/congénito , Anemia/diagnóstico , Anemia/epidemiología , Anemia/terapia , Incompatibilidad de Grupos Sanguíneos/diagnóstico , Incompatibilidad de Grupos Sanguíneos/epidemiología , Incompatibilidad de Grupos Sanguíneos/terapia , Transfusión de Sangre Intrauterina/estadística & datos numéricos , Eritroblastosis Fetal/diagnóstico , Eritroblastosis Fetal/epidemiología , Transfusión de Eritrocitos/estadística & datos numéricos , Femenino , Francia/epidemiología , Humanos , Recién Nacido , Masculino , Embarazo , Resultado del Embarazo/epidemiología , Estudios Retrospectivos , Isoinmunización Rh/epidemiología , Ultrasonografía PrenatalRESUMEN
Jaundice due to unconjugated bilirubin is an everyday condition in the neonatal period because it results from the adaptation of bilirubin metabolism at this time of life. Hyperbilirubinemia has a potential neurotoxicity and although it most often resolves spontaneously, it can lead to acute and sometimes chronic encephalopathy. The latter condition is called kernicterus and induces severe and irreversible neurological sequelae. This rare complication is still reported in all countries throughout the world even if severe hyperbilirubinemia can be prevented and critical points points of failure in jaundice management are identified. Jaundice management are identified, jaundice is the most frequent symptom during the first days of life and after discharge from the maternity ward but also the major cause of readmission in the 15 first days of life. Therefore in the past 20 years, numerous countries have written national practical guidelines for the management of neonatal jaundice using various methodologies. Most of the time, the guidelines resulted from expert consensus more than from an evidence-based argument. The Société française de néonatologie created a working group to provide the first French clinical guidelines for the management of jaundice in the near-term newborn (35 weeks and more). They were written following a physiopathological argument and taking into account both clinical risk factors for severe hyperbilirubinemia and interindividual variability in vulnerability to bilirubin neurotoxicity. Practical tools were also developed to facilitate implementation of the guidelines and are also included.
Asunto(s)
Ictericia Neonatal/diagnóstico , Ictericia Neonatal/terapia , Tamizaje Masivo , Alta del Paciente , Medicina Basada en la Evidencia , Estudios de Seguimiento , Francia , Edad Gestacional , Humanos , Recién Nacido , Neonatología , Readmisión del Paciente , Sociedades MédicasAsunto(s)
Recién Nacido de Bajo Peso , Enfermedades del Prematuro/diagnóstico , Enfermedades del Prematuro/terapia , Ictericia Neonatal/terapia , Sociedades Médicas , Francia , Adhesión a Directriz , Humanos , Recién Nacido , Ictericia Neonatal/diagnóstico , Garantía de la Calidad de Atención de SaludRESUMEN
OBJECTIVES: To assess the performance of middle cerebral artery peak systolic velocity (MCA-PSV) and of the expected daily decrease in fetal hemoglobin in determining the timing of serial in-utero transfusions (IUT) in red-cell alloimmunization. METHODS: This was a retrospective study of a continuous series of suspected anemic fetuses undergoing IUT between June 2003 and December 2012. Doppler measurement of MCA-PSV and pre- and post-transfusion hemoglobin levels were recorded at the time of the first, second and third IUT. Receiver-operating characteristics (ROC) curves and negative and positive predictive values of MCA-PSV in the prediction of severe fetal anemia were calculated. The daily decrease of fetal hemoglobin (Hb) between IUTs was calculated. Regression analysis was used to assess the correlation between pretransfusion fetal hemoglobin and MCA-PSV, and between observed and expected (by projection of daily decreases) pretransfusion fetal hemoglobin levels. RESULTS: One hundred and eleven fetuses required an IUT, of which 96 and 67 received a second and third IUT, respectively. The area under the ROC curve for MCA-PSV in the prediction of severe fetal anemia was not different for each rank of transfusion. The positive predictive value of MCA-PSV decreased from 75.3% at the first IUT, to 46.7% and 48.8% at the second and third IUTs, respectively, while the negative predictive value for a 1.5-MoM threshold remained high (88.9% at the second and 91.7% at the third IUT). The mean daily decrease in hemoglobin following each transfusion was 0.45, 0.35 and 0.32 g/dL, respectively. There was a persistent linear correlation between fetal hemoglobin and MCA-PSV and between observed and expected fetal hemoglobin levels. CONCLUSIONS: Both MCA-PSV and projection of daily decrease in hemoglobin are reliable means of diagnosing fetal anemia following previous IUTs. The high negative predictive value of MCA-PSV could allow subsequent IUTs to be postponed in selected cases.
Asunto(s)
Anemia/terapia , Transfusión de Sangre Intrauterina/métodos , Enfermedades Fetales/terapia , Hemoglobina Fetal/uso terapéutico , Arteria Cerebral Media/fisiopatología , Ultrasonografía Prenatal , Adulto , Anemia/embriología , Velocidad del Flujo Sanguíneo , Femenino , Humanos , Arteria Cerebral Media/diagnóstico por imagen , Embarazo , Complicaciones Hematológicas del Embarazo , Estudios Retrospectivos , Isoinmunización Rh , Factores de Tiempo , Ultrasonografía DopplerRESUMEN
OBJECTIVES: ABO fetomaternal red blood cell incompatibility (ABO FMI) induces an immune hemolysis after fetal transfer of hemolyzing maternal anti-A or anti-B. ABO hemolytic disease (ABO HD) remains the most frequent cause of severe and early jaundice in newborns. High levels of unconjugated hyperbilirubinemia may induce acute and chronic neurological complications. Severe hyperbilirubinemia can be prevented by first-line phototherapy (PT) treatment, but exchange transfusion (ET) is required if treatment is not effective, even if ET is linked with high hemodynamic, infectious, gastrointestinal, and/or biological morbidity. Intravenous human polyclonal immunoglobulins (IVIg) have been proposed in concomitant use with PT in order to avoid the requirement for ET in ABO FMI. METHODS: Electronic databases of all published clinical trials in neonatal hyperbilirubinemia due to ABO incompatibility were systematically queried for randomized controlled clinical trials comparing PT alone to PT associated with IVIg based on the requirement for ET. Duration of PT and adverse events were optional criteria. A meta-analysis of the selected data was performed on six selected trials out of 28 found. RESULTS: IVIg doses ranged from 0.5 to 1.5 g/Kg in one to three administrations. Requirement for ET was lower in the IgIV+PT group, with a relative risk of 0.27 [CI 95% 0.17-0.42; P<0.00001], expressed as a number needed to treat of five neonates to avoid one ET. The mean duration of PT was 4 days in the PT group and association of PT with IVIg significantly reduced the duration of PT treatment by 0.84 days. The tolerance of the IVIg and PT association was good with no reported cases of ulcerative enterocolitis in 265 treated newborns. CONCLUSION: IVIG associated with PT reduces the need for ET and the duration of PT in newborns with hyperbilirubinemia due to ABO hemolytic disease. Their efficacy and good tolerance prompt consideration of IVIg as a therapeutic adjuvant to PT in severe hemolytic hyperbilirubinemia due to ABO incompatibility.
Asunto(s)
Sistema del Grupo Sanguíneo ABO , Incompatibilidad de Grupos Sanguíneos/complicaciones , Hiperbilirrubinemia Neonatal/terapia , Inmunoglobulinas Intravenosas/uso terapéutico , Terapia Combinada , Humanos , Hiperbilirrubinemia Neonatal/etiología , Recién Nacido , FototerapiaAsunto(s)
Kernicterus , Humanos , Recién Nacido , Kernicterus/diagnóstico , Kernicterus/epidemiología , Kernicterus/terapiaAsunto(s)
Pared Abdominal/anomalías , Ascitis/complicaciones , Hidropesía Fetal/etiología , Infecciones por Parvoviridae/complicaciones , Parvovirus B19 Humano , Complicaciones Infecciosas del Embarazo , Ascitis/virología , Femenino , Humanos , Hidropesía Fetal/virología , Recién Nacido , Embarazo , Complicaciones Infecciosas del Embarazo/virologíaRESUMEN
Hemolytic disease of the newborn caused by maternal isoimmunization has been decreasing over the past 10 years because of prophylactic treatment with anti-RH1 (anti-D) immunoglobulin. Nevertheless, there is an increase in the incidence of both relative and absolute numbers of non-RH1 red-cell maternofetal isoimmunizations, essentially anti-RH4 (anti-c), anti-RH3 (anti-E), and anti-Kell. In 8 to 14% of cases, multispecificity antibodies are present, the most common combination being the association of anti-RH3 and -4. Despite absence of specific prophylactic therapy, anti-RH4 isoimmunization could be as severe as anti-RH1 ; as for anti-RH3, it is usually associated with mild to moderate clinical manifestations. Nevertheless, there are few publications on anti-RH3, -4 maternofetal isoimmunization with a bias toward the most severe cases being reported. We report here a case of nonsevere maternofetal anti-RH3, -4 isoimmunization complicated with severe hyperbilirubinemia and delayed profound anemia. Hyperbilirubinemia was controlled using intensive phototherapy. Although anemia was absent at birth, it appeared progressively with a nadir at 7.8 g/dL at 1-month postnatal age. Blood counts were monitored for 3 months but the patient did not require red blood cell transfusion. This report underlines the need for a prolonged and rigorous pediatric follow-up of children born in the context of maternofetal isoimmunization after the acute neonatal period. Furthermore, it stresses the necessity of DAT testing in all pregnant women, even those who are RH1-positive.
Asunto(s)
Isoinmunización Rh/diagnóstico , Isoinmunización Rh/inmunología , Humanos , Recién Nacido , Masculino , Sistema del Grupo Sanguíneo Rh-Hr/inmunologíaRESUMEN
Anti-RhD allo-immunisation has become rare since anti-D prophylaxis was introduced in the seventies; however, it remains the first cause of fetal anemia. It may cause severe fetal complications such as fetal hydrops, cerebral anoxic lesions and fetal death. In the neonatal period, severe jaundices and anemias requiring transfusion or exsanguino-transfusion are still common in case of severe allo-immunisation. Neonatal death and sequellae due to bilirubin encephalopathy have not fully disappeared. Follow-up of pregnancies with maternal allo-immunisation requires identification of the antibody (anti-RhD, anti-Kell and anti-c are the most frequently responsible for fetal complications), dosage and titration. In RhD allo-immunization, feto-maternal incompatibility may be confirmed by non-invasive RHD genotyping of the fetus in maternal blood. In cases at risk for fetal anemia, weekly Doppler assessment of middle cerebral artery peak systolic velocity (MCA-PSV) allows identification of fetal anemia before the occurrence of fetal hydrops. The reference treatment of fetal anemia is in utero fetal transfusion. The risk of fetal loss due to in utero transfusion (IUT) is 3% per procedure. The cumulated risk of fetal loss can thus exceed 10% in case of early occurrence of fetal anemia requiring up to five or six IUTs in a single pregnancy.
Asunto(s)
Incompatibilidad de Grupos Sanguíneos , Anemia/embriología , Anemia/terapia , Incompatibilidad de Grupos Sanguíneos/complicaciones , Incompatibilidad de Grupos Sanguíneos/diagnóstico , Incompatibilidad de Grupos Sanguíneos/terapia , Transfusión de Sangre Intrauterina , Femenino , Muerte Fetal/inmunología , Enfermedades Fetales/terapia , Edad Gestacional , Frecuencia Cardíaca Fetal , Humanos , Hidropesía Fetal/inmunología , Hipoxia Encefálica/inmunología , Recién Nacido , Sistema del Grupo Sanguíneo de Kell/inmunología , Kernicterus/inmunología , Arteria Cerebral Media/diagnóstico por imagen , Arteria Cerebral Media/embriología , Embarazo , Pronóstico , Isoinmunización Rh/complicaciones , Isoinmunización Rh/prevención & control , Globulina Inmune rho(D)/uso terapéutico , Ultrasonografía PrenatalRESUMEN
Non invasive fetal RhD genotyping, based on polymerase-chain-reaction (PCR), is an accurate and validated technique. It allows a reduction by one-third of anti-D immunoglobulin injections to prevent RhD allo-immunization. In case of maternal anti-D immunization, fetal RhD genotyping allows to focus on RhD positive fetuses only the biologic and sonographic follow-up. The wide use of this technique implies the validation and economic evaluation of a commercial RhD genotyping kit, ready for use in non specialized laboratories.
Asunto(s)
Enfermedades Fetales/diagnóstico , Enfermedades Fetales/genética , Diagnóstico Prenatal/métodos , Sistema del Grupo Sanguíneo Rh-Hr/genética , Femenino , Enfermedades Fetales/sangre , Genotipo , Humanos , Intercambio Materno-Fetal , Reacción en Cadena de la Polimerasa/métodos , Embarazo , Sistema del Grupo Sanguíneo Rh-Hr/sangreRESUMEN
OBJECTIVE: To assess the peak systolic velocity in the middle cerebral artery (PSV-MCA) in the prediction of fetal anemia in case of severe red-cell alloimmunization. METHODS: A prospective study, from January 2003 to April 2006, of 47 consecutive pregnancies with severe alloimmunization. Fetal surveillance was based on titration and dosage of antibodies, ultrasound scans, and doppler for PSV-MCA measurement up to twice a week. A fetal blood sampling and in utero transfusion was performed in case of increase in PSV-MCA above 1.5 multiples of the median (MoM), and/or signs of hydrops on ultrasound. Severe fetal anemia was defined by fetal hemoglobin below 0.55MoM for gestational age. Analyses performed included the correlation between PSV-MCA and fetal hemoglobin, the value of PSV-MCA in the prediction of severe fetal anemia, and the determination of adequate threshold for intervention based on ROC curve analysis. RESULTS: Four hundred and eighty-five PSV-MCA were performed in 47 high-risk pregnancies, of which 125 were coupled with hemoglobin measurement by fetal blood sampling. There is a significant negative correlation between PSV-MCA and fetal hemoglobin (R2=0.6545 ; p<0.0001). Based on all prospective data, the negative predictive value of PSV-MCA was 97.8 %, sensitivity was 86.7 %, with a false positive rate of 12.2%. Area under the ROC curve was 0.85 (IC 95 %, 0.742-0.927 ; p<0.0001), suggesting an excellent value of this test. When switching the threshold for intervention from 1.5 to 1.6MoM, the positive predictive value increased, without decrease in sensitivity or negative predictive value. CONCLUSION: This study confirms the correlation between PSV-MCA and fetal hemoglobin. It allows a decrease of invasive procedures in the follow-up of pregnancies with severe red-cell alloimmunization.
Asunto(s)
Anemia/diagnóstico por imagen , Velocidad del Flujo Sanguíneo , Transfusión de Sangre Intrauterina/métodos , Enfermedades Fetales/diagnóstico por imagen , Hemoglobina Fetal/análisis , Arteria Cerebral Media/diagnóstico por imagen , Isoinmunización Rh/complicaciones , Anemia/sangre , Anemia/diagnóstico , Femenino , Enfermedades Fetales/sangre , Enfermedades Fetales/diagnóstico , Humanos , Arteria Cerebral Media/fisiología , Valor Predictivo de las Pruebas , Embarazo , Estudios Prospectivos , Curva ROC , Flujo Sanguíneo Regional , Isoinmunización Rh/diagnóstico por imagen , Isoinmunización Rh/terapia , Factores de Riesgo , Ultrasonografía PrenatalRESUMEN
Anti-D prophylaxis should be proposed to all RhD negative non-sensitized pregnant women, after delivering an information concerning both Rhesus disease and anti-D immunoglobulins. This information must be delivered as a written document and the patient's oral consent is required before administration of the anti-D immunoglobulins. Anti-D immunoglobulins currently used in France for prophylaxis are extracted from plasma of hyperimmunized paid donors. Even if all the conditions of viral safety are fulfilled in the preparation of anti-D immunoglobulins, they remain blood derived products. As such, prescription of anti-D immunoglobulins should follow legal rules concerning tracability and information. Refusal of rhesus prophylaxis can occur but should be transcribed and motivated in the patient's chart. Administration of anti-D immunoglobulins is usually well tolerated. Reactions to hemolysis of fetal Rhesus positive red cells can occur but remain rare and linked to important foeto-maternal hemorrhage. They can be easily prevented or treated by anti-inflammatory drugs. Patients can be vaccinated against rubella in the post-partum period even though they will receive a concomitant prophylaxis with Rh immunoglobulin. Persistence of passive anti-D in maternal circulation after injection lasts several weeks or months and could have various consequences. In the mother: it can interfere with diagnosis of active anti-D immunization. In most cases, it may be possible to differentiate passive and immune anti-D. When reliable information concerning date and dosage of antenatal anti-D prophylaxis are available. In the newborn: anti-D immunoglobulins can pass through the placenta and enter the fetal circulation, coat the D positive fetal red cells and give positive DAT. Positive DAT is reported in 5 to 15% of the newborns following rhesus prophylaxis in the third trimester but with no report of anemia or jaundice. In absence of ABO incompatibility, no additional investigation is needed in these newborns.
Asunto(s)
Eritroblastosis Fetal/prevención & control , Inmunización Pasiva , Educación del Paciente como Asunto , Isoinmunización Rh/prevención & control , Globulina Inmune rho(D) , Femenino , Francia , Humanos , Recién Nacido , Consentimiento Informado , Isoanticuerpos/efectos adversos , Isoanticuerpos/inmunología , Isoanticuerpos/uso terapéutico , Embarazo , Sistema del Grupo Sanguíneo Rh-Hr/inmunología , Globulina Inmune rho(D)/efectos adversos , Globulina Inmune rho(D)/inmunología , Globulina Inmune rho(D)/uso terapéutico , Factores de Riesgo , Resultado del TratamientoRESUMEN
At present, rhesus prophylaxis concerns RhD negative pregnant women, even though 30 to 40% of them are bearing a RhD negative child. Knowing the RhD fetal genotype could change this quite irrational practice of prophylaxis (exposing many more women than needed to blood derived products) without reducing its efficacy. RhD fetal genotype determined on amniotic fluid has an excellent sensitivity. Presence of silent D genes slightly impairs its specificity which remains acceptable. However women have to be informed of possible false positives. Fetal RhD genotyping on maternal blood is more complex. Sensitivity is good from 10 GW and excellent after 15 GW. In case of a first negative result, it is recommended to control fetal RhD on a second sample drawn a few weeks later. Another new perspective for rhesus prophylaxis is the attempt to substitute polyclonal IgG anti-D into human monoclonal IgG anti-D. The main difficulty is to elaborate monoclonal antibodies with a capacity to neutralize RhD positive red blood cells equivalent to those of polyclonal anti-D. A new generation of antibodies is in process and preliminary clinical results are suggesting a possible use of these monoclonal antibodies for future rhesus prophylaxis but long-term follow-up is required to draw further conclusions.
Asunto(s)
Sangre Fetal/inmunología , Enfermedades Fetales/genética , Isoinmunización Rh/prevención & control , Sistema del Grupo Sanguíneo Rh-Hr/genética , Globulina Inmune rho(D)/uso terapéutico , Eritroblastosis Fetal/diagnóstico , Eritroblastosis Fetal/genética , Femenino , Enfermedades Fetales/diagnóstico , Genotipo , Humanos , Recién Nacido , Reacción en Cadena de la Polimerasa , Embarazo , Diagnóstico Prenatal , Globulina Inmune rho(D)/inmunología , Sensibilidad y EspecificidadRESUMEN
RhD prophylaxis concerns RhD negative women, who are non-sensitized against D antigen during and at the end of their pregnancy with a RhD positive child. RhD prophylaxis includes targeted prophylaxis (prevention of anti-D immunization after feto-maternal hemorrhage (FMH) induced by prenatal events and delivery) and routine antenatal D prophylaxis (prevention of anti-D immunization resulting from spontaneous FMH in the last trimester of pregnancy). Targeted prophylaxis should be applied regardless of the gestational age and a dose of 100microg anti-D is usually enough (200microg is the lowest dosage currently available in France). However it is recommended to quantify the volume of feto-maternal hemorrhage to avoid administration of a dose of IgG anti-D less than 20microg per ml of fetal red blood cells. Efficacy of prophylaxis relies also on the delay between the sensitizing event and the injection of anti-D, delay should be less than 72 hours. Intravenous administration of anti-D allows immediate neutralization of D positive fetal red blood cells and should be, if possible, preferred to intramuscular administration (IM). After a first injection of anti-D, if repetition of potential sensitizing events occurs, abstention of prophylaxis is possible depending on the previous administrated dose (protection lasts 6 weeks for 200microg and 9 weeks for 300microg) and the amount of feto-maternal hemorrhage. For routine prophylaxis of the third trimester, 300microg of anti-D should be proposed IM at 281+/-GW. Abstention of Rh prophylaxis is possible if the alleged father is certified RhD negative or if the fetal RhD genotype is confirmed negative. At delivery, RhD phenotype of the newborn should be determined even if RhD fetal genotype is known. Maternal blood should be drawn for quantification of feto-maternal transfusion at least 30 min after delivery is completed.
Asunto(s)
Isoanticuerpos/uso terapéutico , Isoinmunización Rh/prevención & control , Sistema del Grupo Sanguíneo Rh-Hr , Globulina Inmune rho(D)/uso terapéutico , Transfusión Sanguínea , Relación Dosis-Respuesta Inmunológica , Femenino , Humanos , Recién Nacido , Embarazo , Globulina Inmune rho(D)/inmunología , Factores de Riesgo , Resultado del TratamientoRESUMEN
With improvement of critical care of the newborn, perinatal mortality had decreased along the past decades. However, recent studies have shown that there is a slightly increase in the prevalence of cerebral palsy over the same period either for term or premature babies. Epidemiological data stress the multifactorial origins of cerebral palsy. Along with premature birth one of the predominant cause appears to be chorioamnionitis. Using data from a review of clinical and experimental studies the authors aim to clarify the link between infection, inflammation and fetal brain damage. The hypothesis that cytokines as mediators of inflammation can also mediate neurotoxicity is developed.